Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Oct 21, 2014
Tekmira Provides Periodic Update on TKM-Ebola Program

Oct 15, 2014
Tekmira Presents Results of Preclinical Studies With Hepatitis B Therapeutic


View all »Events & Presentations

Oct 15, 2014
10th Annual Meeting of the Oligonucleotide Therapeutics Society

Oct 7, 2014
2014 BIO Investor Forum